FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013017838> ?p ?o ?g. }

• W2013017838 endingPage "234" @default.
• W2013017838 startingPage "230" @default.
• W2013017838 abstract "No AccessJournal of UrologyINVESTIGATIVE UROLOGY1 Jul 2003Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome DEREK A. HAUSLADEN, MARCIA A. WHEELER, DARIO C. ALTIERI, JOHN W. COLBERG, and ROBERT M. WEISS DEREK A. HAUSLADENDEREK A. HAUSLADEN More articles by this author , MARCIA A. WHEELERMARCIA A. WHEELER More articles by this author , DARIO C. ALTIERIDARIO C. ALTIERI More articles by this author , JOHN W. COLBERGJOHN W. COLBERG More articles by this author , and ROBERT M. WEISSROBERT M. WEISS More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000063685.29339.24AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Urine survivin is a predictive/prognostic molecular marker that detects transitional cell carcinoma (TCC) with high specificity and sensitivity. The presence of urine survivin in patients with TCC who receive intravesical instillation of bacillus Calmette-Guerin or mitomycin C may predict recurrence. Materials and Methods: Urine from 25 subjects receiving 27 intravesical treatments of bacillus Calmette-Guerin or mitomycin C for TCC were collected prior to, during and after treatment. Urinary survivin levels were compared with outcome, as assessed by cytology and cystoscopy with or without biopsy 1 month and up to 12 months after the completion of treatment. Results: Pretreatment survivin levels were higher in subjects in whom TCC recurred following treatment compared with those who achieved remission. Survivin levels increased several-fold during treatment with the highest survivin levels measured in subjects with recurrence. Median posttreatment values of survivin were zero in those who achieved remission and 1.0 ng/ml urine in subjects in whom TCC recurred. Conclusions: The presence of urinary survivin 1 month after the completion of treatment predicts TCC recurrence with 100% sensitivity and 78% specificity. Specificity to predict TCC recurrence increases to 92% after 1 year. No TCC recurred for 1 year in 12 of the 14 subjects with a posttreatment survivin level of 0.1 ng or less per ml urine. Three of the 4 subjects who were survivin positive but in remission 1 month after the completion of treatment had recurrent TCC within 1 year. Subjects who have urinary survivin after the completion of intravesical instillation have a high likelihood of TCC recurrence. References 1 : Control of apoptosis and mitotic spindle checkpoint by survivin. Nature1998; 396: 580. Google Scholar 2 : Analysis of human transcriptomes. Nature Genet1999; 23: 387. Google Scholar 3 : Expression of survivin and Bcl-2 in the normal human endometrium. Mole Hum Reprod2000; 6: 529. Google Scholar 4 : A novel anti-apoptosis gene, survivin, expressed in cancer. Nature Med1997; 3: 917. Google Scholar 5 : Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med1999; 341: 452. Google Scholar 6 : Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet1998; 351: 882. Google Scholar 7 : High expression of Survivin mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma. Oncogene2000; 19: 617. Google Scholar 8 : Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res2000; 6: 127. Google Scholar 9 : A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol1999; 17: 2100. Google Scholar 10 : Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int J Cancer2001; 95: 92. Google Scholar 11 : Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res1998; 58: 5071. Google Scholar 12 : BCG immunotherapy of bladder cancer: 20 years on. Lancet1999; 353: 1689. Google Scholar 13 : Mitomycin C: a clinical update. Cancer Treat Rev2001; 27: 35. Google Scholar 14 : Urine detection of survivin and diagnosis of bladder cancer. JAMA2001; 285: 324. Google Scholar 15 : Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. J Invest Dermatol1999; 113: 1076. Google Scholar 16 : Stage TA-T1 bladder cancer: the relationship between findings at first followup cystoscopy and subsequent recurrence and progression. J Urol2002; 167: 1634. Link, Google Scholar 17 : Prognostic factors for recurrence and followup policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party). J Urol1989; 142: 284. Link, Google Scholar 18 : Follow-up of patients with “superficial” transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol1993; 72: 135. Google Scholar 19 : Current bladder tumor tests: does their projected utility fulfill clinical necessity?. J Urol2001; 165: 1067. Link, Google Scholar 20 : Bladder cancer detection with urinary survivin, an inhibitor of apoptosis. Front Biosci2002; 7: e36. Google Scholar From the Departments of Surgery and Pathology, Yale University School of Medicine, New Haven, Connecticut© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byCui M, Au J, Wientjes M, O'Donnell M, Loughlin K and Lu Z (2018) Intravenous siRNA Silencing of Survivin Enhances Activity of Mitomycin C in Human Bladder RT4 XenograftsJournal of Urology, VOL. 194, NO. 1, (230-237), Online publication date: 1-Jul-2015.Wosnitzer M, Domingo-Domenech J, Castillo-Martin M, Ritch C, Mansukhani M, Petrylack D, Benson M, McKiernan J and Cordon-Cardo C (2018) Predictive Value of Microtubule Associated Proteins Tau and Stathmin in Patients With Nonmuscle Invasive Bladder Cancer Receiving Adjuvant Intravesical Taxane TherapyJournal of Urology, VOL. 186, NO. 5, (2094-2100), Online publication date: 1-Nov-2011.DAVIES B, CHEN J, MODUGNO F, WEISSFELD J, LANDSITTEL D, DHIR R, NELSON J and GETZENBERG R (2018) CONTRIBUTION OF THE PROSTATE LIMITS THE USEFULNESS OF SURVIVIN FOR THE DETECTION OF BLADDER CANCERJournal of Urology, VOL. 174, NO. 5, (1767-1770), Online publication date: 1-Nov-2005. Volume 170Issue 1July 2003Page: 230-234 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.KeywordsMycobacterium bovistumor markers, biologicalcarcinoma, transitional cellbladdermitomycinMetricsAuthor Information DEREK A. HAUSLADEN More articles by this author MARCIA A. WHEELER More articles by this author DARIO C. ALTIERI More articles by this author JOHN W. COLBERG More articles by this author ROBERT M. WEISS More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2013017838 created "2016-06-24" @default.
• W2013017838 creator A5052083936 @default.
• W2013017838 creator A5060464452 @default.
• W2013017838 creator A5065287199 @default.
• W2013017838 creator A5082346201 @default.
• W2013017838 creator A5003063675 @default.
• W2013017838 date "2003-07-01" @default.
• W2013017838 modified "2023-09-29" @default.
• W2013017838 title "Effect of Intravesical Treatment of Transitional Cell Carcinoma With Bacillus Calmette-Guerin and Mitomycin C on Urinary Survivin Levels and Outcome" @default.
• W2013017838 cites W1578797961 @default.
• W2013017838 cites W1662899239 @default.
• W2013017838 cites W1768187423 @default.
• W2013017838 cites W1918156452 @default.
• W2013017838 cites W1967631773 @default.
• W2013017838 cites W1972304655 @default.
• W2013017838 cites W1973115319 @default.
• W2013017838 cites W1985068997 @default.
• W2013017838 cites W1988936558 @default.
• W2013017838 cites W2026553119 @default.
• W2013017838 cites W2035523654 @default.
• W2013017838 cites W2077150898 @default.
• W2013017838 cites W2101706701 @default.
• W2013017838 cites W2155523608 @default.
• W2013017838 cites W2155913947 @default.
• W2013017838 cites W2314256590 @default.
• W2013017838 cites W2329506722 @default.
• W2013017838 cites W2392046186 @default.
• W2013017838 doi "https://doi.org/10.1097/01.ju.0000063685.29339.24" @default.
• W2013017838 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12796695" @default.
• W2013017838 hasPublicationYear "2003" @default.
• W2013017838 type Work @default.
• W2013017838 sameAs 2013017838 @default.
• W2013017838 citedByCount "48" @default.
• W2013017838 countsByYear W20130178382012 @default.
• W2013017838 countsByYear W20130178382013 @default.
• W2013017838 countsByYear W20130178382014 @default.
• W2013017838 countsByYear W20130178382015 @default.
• W2013017838 countsByYear W20130178382016 @default.
• W2013017838 countsByYear W20130178382018 @default.
• W2013017838 countsByYear W20130178382019 @default.
• W2013017838 countsByYear W20130178382020 @default.
• W2013017838 crossrefType "journal-article" @default.
• W2013017838 hasAuthorship W2013017838A5003063675 @default.
• W2013017838 hasAuthorship W2013017838A5052083936 @default.
• W2013017838 hasAuthorship W2013017838A5060464452 @default.
• W2013017838 hasAuthorship W2013017838A5065287199 @default.
• W2013017838 hasAuthorship W2013017838A5082346201 @default.
• W2013017838 hasConcept C121608353 @default.
• W2013017838 hasConcept C126322002 @default.
• W2013017838 hasConcept C126894567 @default.
• W2013017838 hasConcept C141071460 @default.
• W2013017838 hasConcept C143998085 @default.
• W2013017838 hasConcept C2775975398 @default.
• W2013017838 hasConcept C2778065480 @default.
• W2013017838 hasConcept C2779150676 @default.
• W2013017838 hasConcept C2779338040 @default.
• W2013017838 hasConcept C2780352672 @default.
• W2013017838 hasConcept C502942594 @default.
• W2013017838 hasConcept C71924100 @default.
• W2013017838 hasConcept C86803240 @default.
• W2013017838 hasConcept C89423630 @default.
• W2013017838 hasConceptScore W2013017838C121608353 @default.
• W2013017838 hasConceptScore W2013017838C126322002 @default.
• W2013017838 hasConceptScore W2013017838C126894567 @default.
• W2013017838 hasConceptScore W2013017838C141071460 @default.
• W2013017838 hasConceptScore W2013017838C143998085 @default.
• W2013017838 hasConceptScore W2013017838C2775975398 @default.
• W2013017838 hasConceptScore W2013017838C2778065480 @default.
• W2013017838 hasConceptScore W2013017838C2779150676 @default.
• W2013017838 hasConceptScore W2013017838C2779338040 @default.
• W2013017838 hasConceptScore W2013017838C2780352672 @default.
• W2013017838 hasConceptScore W2013017838C502942594 @default.
• W2013017838 hasConceptScore W2013017838C71924100 @default.
• W2013017838 hasConceptScore W2013017838C86803240 @default.
• W2013017838 hasConceptScore W2013017838C89423630 @default.
• W2013017838 hasIssue "1" @default.
• W2013017838 hasLocation W20130178381 @default.
• W2013017838 hasLocation W20130178382 @default.
• W2013017838 hasOpenAccess W2013017838 @default.
• W2013017838 hasPrimaryLocation W20130178381 @default.
• W2013017838 hasRelatedWork W2013017838 @default.
• W2013017838 hasRelatedWork W2363128294 @default.
• W2013017838 hasRelatedWork W2384311157 @default.
• W2013017838 hasRelatedWork W2421821834 @default.
• W2013017838 hasRelatedWork W2562915339 @default.
• W2013017838 hasRelatedWork W2795637274 @default.
• W2013017838 hasRelatedWork W4281756357 @default.
• W2013017838 hasRelatedWork W4303057512 @default.
• W2013017838 hasRelatedWork W4313197990 @default.
• W2013017838 hasRelatedWork W2118673085 @default.
• W2013017838 hasVolume "170" @default.
• W2013017838 isParatext "false" @default.
• W2013017838 isRetracted "false" @default.
• W2013017838 magId "2013017838" @default.
• W2013017838 workType "article" @default.